Annual core operating profit increased in 2024 for British pharmaceutical company GSK compared to 2023, the company reported ...

The execs at Haleon, a huge multinational consumer products company, ought to take a good look in the mirror. That is, unless misleading, sleazy marketing is in their mission statement. In that case, ...

That brand is more than just a logo - it’s your company’s ... of consumer marketing can be brought into the B2B pharmaceutical world. If GSK were to make a John Lewis-esque Christmas ad ...

The new money means that iTeos can now fund its activities through 2027, including the start of multiple phase 3 studies of belrestotug in combination with GSK ... and Logos Capital, as well ...

Bearish flow noted in GSK (GSK) Pharma with 1,131 puts trading, or 2x expected. Most active are Mar-25 33 puts and Jan-26 35 puts, with total volume in those strikes near 730 contracts. The Put/Call ...

Despite significant dips in its vaccines sales, the British pharma narrowly beat consensus estimates for Q4 2024 and raised ...

GSK is prioritizing development of its hepatitis B treatment bepirovirsen as the pharma ends work on another potential ...

Q4 2024 dividend of 16p declared; 61p FY 2024; 64p expected for 2025. GSK (GSK) now intends to commence a GBP 2B share buyback programme, to be ...

GSK's Q4 sales hit $10.40 billion, topping estimates. Specialty Medicines grew 14%, while vaccines declined. The company ...

The pharmaceutical company said promising pipeline developments and high demand for drugs in its specialty segment lifted ...

GSK launched a 2 billion pounds ($2.5 billion) share buyback on Wednesday and lifted its long-term sales target to nearly $50 ...

GlaxoSmithKline plc (NYSE: NYSE:GSK) shares gained 5.65% after the pharmaceutical giant reported fourth quarter revenue that beat analyst estimates, despite earnings falling short of expectations.